Genetic Technologies Limited (GENE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genetic Technologies Limited (GENE) trades at $0.77 with AI Score 43/100 (Grade C). Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools for women's health. Market cap: $111.24M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GENE: GENE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GENE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GENE: the 1 perspectives are evenly split.
How is this calculated? →Genetic Technologies Limited (GENE) Healthcare & Pipeline Overview
Genetic Technologies Limited is a molecular diagnostics company providing predictive testing for women's health, primarily through its BREVAGenplus breast cancer risk assessment. Operating in the medical diagnostics sector, the company focuses on expanding its GeneType platform to include various disease risk assessments in both Australia and the United States.
What Is the Investment Thesis for GENE?
Genetic Technologies Limited presents a speculative investment thesis centered on its BREVAGenplus and GeneType platforms for disease risk assessment. The company's potential lies in expanding its product offerings and market reach within the growing predictive diagnostics market. Key value drivers include increasing adoption of BREVAGenplus by healthcare providers and successful development and commercialization of new GeneType tests for diseases like cardiovascular disease and type 2 diabetes. The company's gross margin of 50.9% indicates pricing power. However, its negative P/E ratio of -0.45 and profit margin of -156.8% highlight significant profitability challenges. Ongoing: The company's ability to achieve profitability and manage its cash burn will be critical for long-term success.
Based on FMP financials and quantitative analysis
GENE Key Highlights
- Market capitalization of $111.24M, reflecting its small-cap status within the healthcare sector.
- Gross margin of 50.9%, indicating a strong ability to control the cost of goods sold.
- Negative P/E ratio of -0.45, suggesting the company is currently unprofitable.
- Profit margin of -156.8%, highlighting significant challenges in achieving profitability.
- Beta of 0.48, indicating lower volatility compared to the overall market.
Who Are GENE's Competitors?
GENE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AUGX Augmedix, Inc. | $2.35 | -0.21% | $115.91M | 58 |
| CYT Cyteir Therapeutics, Inc. | $3.02 | -2.27% | $108.71M | 47 |
| GTH Genetron Holdings Limited | $4.03 | +0.12% | $127.29M | 61 |
| HLVX HilleVax, Inc. | $2.09 | -0.48% | $104.76M | 47 |
| ICAD iCAD, Inc. | $3.87 | +3.75% | $106.31M | 54 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GENE's Key Strengths?
- Clinically validated BREVAGenplus test.
- Expanding GeneType product line.
- Research and collaboration agreements with leading institutions.
- Expertise in genetic testing and personalized medicine.
What Are GENE's Weaknesses?
- Negative profitability and high operating expenses.
- Limited market share compared to larger competitors.
- Dependence on a small number of products for revenue.
- Small company size with 55 employees.
What Could Drive GENE Stock Higher?
- Expansion of the GeneType test menu to include additional disease risk assessments, such as cardiovascular disease and type 2 diabetes. This could drive revenue growth and increase market share.
- Increased adoption of BREVAGenplus by healthcare providers and patients. This will depend on the company's marketing efforts and the clinical validation of the test.
- Strategic partnerships and collaborations with research institutions and healthcare providers. These partnerships could expand the company's product offerings and market reach.
- Positive results from clinical trials and studies evaluating the effectiveness of its tests. This could increase confidence in the company's products and drive adoption.
What Are the Key Risks for GENE?
- Financial-distress signal — its Altman Z-Score of -24.59 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established diagnostics companies with greater resources and market share. This could limit the company's ability to grow its revenue and market share.
- Changes in healthcare regulations and reimbursement policies. This could negatively impact the demand for the company's products and services.
- Patent expiration and intellectual property challenges. This could allow competitors to copy the company's products and reduce its competitive advantage.
- The company's negative profitability and high operating expenses. This could lead to financial difficulties and the need to raise additional capital.
- Reliance on a small number of products for revenue. This makes the company vulnerable to changes in demand for those products.
What Are the Growth Opportunities for GENE?
- Expansion of GeneType product line: Genetic Technologies has the opportunity to expand its GeneType platform to include risk assessment tests for diseases such as cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma. The market for these tests is substantial, with cardiovascular disease alone affecting millions of people worldwide. Successful development and commercialization of these tests could significantly increase the company's revenue and market share. Timeline: 2-3 years for initial test launches.
- Increased adoption of BREVAGenplus: Genetic Technologies can increase the adoption of its BREVAGenplus breast cancer risk assessment test by expanding its marketing efforts and targeting healthcare professionals in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. The market for breast cancer risk assessment is growing, driven by increasing awareness of the importance of early detection. Timeline: Ongoing.
- Geographic expansion: Genetic Technologies currently operates in Australia and the United States. Expanding into other geographic markets, such as Europe and Asia, could significantly increase the company's revenue and market share. These markets have a growing demand for genetic testing and personalized medicine. Timeline: 3-5 years for significant expansion.
- Strategic partnerships and collaborations: Genetic Technologies can leverage strategic partnerships and collaborations with research institutions, healthcare providers, and other companies to expand its product offerings, market reach, and scientific knowledge base. The company already has research agreements with several universities and research institutes. Timeline: Ongoing.
- Development of personalized medicine solutions: Genetic Technologies can leverage its expertise in genetic testing to develop personalized medicine solutions that tailor treatment plans to individual patients based on their genetic profiles. The market for personalized medicine is growing rapidly, driven by advancements in genomics and proteomics. Timeline: 5+ years for significant impact.
What Opportunities Does GENE Have?
- Expansion into new geographic markets.
- Development of personalized medicine solutions.
- Increased adoption of BREVAGenplus and GeneType tests.
- Strategic partnerships and collaborations.
What Threats Does GENE Face?
- Competition from established diagnostics companies.
- Changes in healthcare regulations and reimbursement policies.
- Patent expiration and intellectual property challenges.
- Technological advancements that could render its products obsolete.
What Are GENE's Competitive Advantages?
- Proprietary technology and intellectual property related to its BREVAGenplus and GeneType tests.
- Established relationships with healthcare providers and research institutions.
- Clinical validation of its BREVAGenplus test.
- Expertise in genetic testing and personalized medicine.
What Does GENE Do?
Genetic Technologies Limited, established in 1987 and headquartered in Fitzroy, Australia, is a molecular diagnostics company specializing in predictive testing and assessment tools. The company focuses on helping physicians manage women's health through early risk detection. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test designed to predict non-hereditary breast cancer risk. This test is marketed to healthcare professionals, including those in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. Beyond BREVAGenplus, Genetic Technologies offers a range of cancer risk assessment tests under the GeneType brand, covering colorectal and breast cancer. The company is also developing risk assessment tests for other diseases, including cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma, aiming to broaden its diagnostic offerings. Additionally, Genetic Technologies provides genetic testing services for medical, animal, forensic, and plant applications, diversifying its revenue streams. Genetic Technologies has established research and collaboration agreements with several institutions, including the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom, to support its research and development efforts and expand its scientific knowledge base.
What Products and Services Does GENE Offer?
- Develops and commercializes predictive testing and assessment tools.
- Offers BREVAGenplus, a risk assessment test for non-hereditary breast cancer.
- Markets GeneType for Colorectal Cancer and GeneType for Breast Cancer.
- Develops risk assessment tests for cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma.
- Provides genetic testing services for medical, animal, forensic, and plant applications.
- Collaborates with research institutions to expand its scientific knowledge base.
How Does GENE Make Money?
- Generates revenue through the sale of its BREVAGenplus and GeneType risk assessment tests.
- Provides genetic testing services to various industries, including medical, animal, forensic, and plant.
- Partners with healthcare providers and research institutions to expand its market reach and product offerings.
What Industry Does GENE Operate In?
Genetic Technologies Limited operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for personalized medicine. The market for genetic testing is projected to grow, driven by advancements in technology and a growing awareness of the benefits of early disease detection. The company faces competition from established players like Exact Sciences (CYT) and smaller, specialized diagnostics firms. Success in this industry requires continuous innovation, strong intellectual property protection, and effective marketing to healthcare providers.
Who Are GENE's Key Customers?
- Healthcare professionals, including those in breast health and imaging centers.
- Obstetricians/gynecologists.
- Breast cancer risk assessment specialists, such as breast surgeons.
- Individuals seeking genetic testing services.
Net buyingInsider Activity
The most recent 11 insider filings for Genetic Technologies Limited break down as 3 sales and 8 purchases. On net that is roughly 62K shares acquired (about $284K) — insiders putting money in tends to read as conviction.
GENE Valuation & Market Position
With a $111.24M market cap, Genetic Technologies Limited sits in the micro-cap segment of the market. Relative to its peer group, GENE's quantitative score of 43/100 is below the peer average of 53/100.
F-Score 2/9Financial Health
Genetic Technologies Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.59 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Genetic Technologies Limited revenue of about $26.4M for fiscal 2026, with EPS near $0.00.
Company Profile
Genetic Technologies Limited operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Fitzroy, AU. The company is led by CEO Kevin Camilleri. GENE has traded publicly since 2005.
GENE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in GENE's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and upcoming trials.
- Increased media coverage around genetic testing has raised awareness, potentially boosting the company's visibility and interest.
- Collaborations with research institutions have garnered excitement, suggesting a strong pipeline and future growth opportunities.
Bear Case
- Concerns about cash flow sustainability have emerged, as some analysts question the company's ability to fund ongoing projects without further dilution.
- Recent social sentiment shows skepticism regarding the competitive landscape, with many believing that rivals have stronger offerings.
- Market perception remains cautious due to the volatility in the biotech sector, which has seen mixed results from similar companies recently.
- Insider selling activity has raised eyebrows, leading to fears that those within the company might not share the same optimism as before.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GENE Latest News
-
Rollins: A Rare Generational Wealth-Building Opportunity (Rating Upgrade)
All Articles on Seeking Alpha · Jun 29, 2026
-
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
zacks.com · Jun 1, 2026
-
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
prnewswire.com · May 29, 2026
-
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
globenewswire.com · May 22, 2026
GENE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GENE.
Price Targets
Wall Street price target analysis for GENE.
GENE MoonshotScore
What does this score mean?
The MoonshotScore rates GENE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Rollins: A Rare Generational Wealth-Building Opportunity (Rating Upgrade)
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
Latest Genetic Technologies Limited Analysis
Leadership: Kevin Camilleri
Managing Director
Kevin Camilleri serves as the Managing Director of Genetic Technologies Limited. His background includes experience in managing and leading teams within the biotechnology sector. He is responsible for overseeing the company's strategic direction, operations, and financial performance. Camilleri's leadership is focused on driving growth through the expansion of the company's product offerings and market reach.
Track Record: Under Kevin Camilleri's leadership, Genetic Technologies has focused on expanding its GeneType platform and increasing the adoption of its BREVAGenplus test. He has overseen the company's research and collaboration agreements with various institutions. His tenure has been marked by efforts to improve the company's financial performance and achieve profitability.
Genetic Technologies Limited ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. GENE functions as a Level 2 ADR, meaning it is traded on an exchange but was not necessarily issued to raise capital. This allows U.S. investors to invest in Genetic Technologies Limited more conveniently.
- Home Market Ticker: Australian Securities Exchange (ASX), Australia
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About Genetic Technologies Limited (GENE) — Healthcare
What does Genetic Technologies Limited do?
Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools, primarily in women's health. Its main product is BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also offers GeneType tests for colorectal and breast cancer, and it is developing tests for other diseases like cardiovascular disease and type 2 diabetes. Additionally, Genetic Technologies provides genetic testing services for medical, animal, forensic, and plant applications, serving a diverse range of customers.
What are the main risks for GENE?
Genetic Technologies Limited faces several key risks. Competition from larger, more established diagnostics companies poses a significant threat. Changes in healthcare regulations and reimbursement policies could negatively impact demand for its products. Patent expiration and intellectual property challenges could erode its competitive advantage. The company's current negative profitability and reliance on a limited product portfolio also present financial and operational risks. Successfully mitigating these risks is crucial for the company's long-term success.
How does Genetic Technologies Limited generate revenue in the healthcare sector?
Genetic Technologies Limited primarily generates revenue through the sale of its predictive testing and assessment tools, particularly BREVAGenplus and the GeneType series of tests. These tests are marketed to healthcare professionals, including those in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. Revenue is also derived from genetic testing services offered to medical clients. The company's ability to expand its test menu and increase adoption of its existing products will be critical for driving revenue growth in the healthcare sector.
How does Genetic Technologies Limited protect its intellectual property and maintain a competitive edge?
Genetic Technologies Limited relies on patents and proprietary technology to protect its intellectual property and maintain a competitive edge in the molecular diagnostics market. The company's BREVAGenplus test and GeneType platform are based on unique algorithms and methodologies. Ongoing research and development efforts are focused on developing new and improved tests, as well as expanding the company's patent portfolio. Strategic collaborations with research institutions also contribute to the company's intellectual property and competitive position.
What are the key factors to evaluate for GENE?
Genetic Technologies Limited (GENE) holds an AI score of 43/100 (low). Not financial advice.
How frequently does GENE data refresh on this page?
GENE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GENE's recent stock price performance?
Genetic Technologies Limited (GENE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Clinically validated BREVAGenplus test. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GENE overvalued or undervalued right now?
Valuing Genetic Technologies Limited (GENE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- AI analysis pending may reveal new insights.